Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00HTY
|
|||
| Former ID |
DIB018020
|
|||
| Drug Name |
PGF2alpha
|
|||
| Synonyms |
Amoglandin; Cerviprost; Cyclosin; Enzaprost; Panacelan; prostaglandin F2alpha
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Clinical trial | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H34O5
|
|||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O
|
|||
| InChI |
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|
|||
| InChIKey |
PXGPLTODNUVGFL-YNNPMVKQSA-N
|
|||
| CAS Number |
CAS 551-11-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3912, 613198, 4265953, 7847149, 7980284, 8143215, 8616237, 14852168, 15398784, 26754609, 29216066, 39289529, 47588758, 47588759, 48258963, 48415906, 50026801, 50110092, 53789218, 56311306, 56313004, 56313208, 57357710, 77668180, 92308787, 92309910, 99300824, 99302342, 103214323, 103943633, 104046437, 113853160, 124892254, 124892255, 125307573, 126662422, 134340899, 134978425, 135651540, 137006907, 142063920, 144205330, 162205063, 175268163, 175607780, 176484109, 179116866, 211534905, 223673680, 226412676
|
|||
| ChEBI ID |
CHEBI:15553
|
|||
| ADReCS Drug ID | BADD_D00682 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Stereocontrolled organocatalytic synthesis of prostaglandin PGF2alpha in seven steps. Nature. 2012 Sep 13;489(7415):278-81. | |||
| REF 2 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | |||
| REF 3 | Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. | |||
| REF 4 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | |||
| REF 5 | Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. | |||
| REF 6 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. | |||
| REF 7 | Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.